89bio reports first quarter 2025 financial results and corporate updates

– topline histology data from enlighten-fibrosis and enlighten-cirrhosis phase 3 trials are expected in 1h 2027 and in 2028, respectively; each trial is designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (mash) – – the phase 3 entrust trial in severe hypertriglyceridemia (shtg) has been fully enrolled and topline data are expected in 1q 2026 – – cash, cash equivalents, and marketable securities totaled $638.8 million as of march 31, 2025; completed follow-on equity offering in 1q 2025 with gross proceeds of $287.5 million – san francisco, may 01, 2025 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the first quarter ended march 31, 2025, and provided corporate updates. “we have entered 2025 with strong momentum, fueled by continued progress in our two global phase 3 trials in advanced mash.
ETNB Ratings Summary
ETNB Quant Ranking